# Health and Pharma — Full LLM Context

> This file provides comprehensive context about Health and Pharma for large language models.
> For a summary, see: https://healthandpharma.net/llms.txt

## Categories

- **Dermatology** (0 articles) — https://healthandpharma.net/posts?category=dermatology
- **Medicines** (0 articles) — https://healthandpharma.net/posts?category=medicines
- **Infections** (4 articles) — https://healthandpharma.net/posts?category=infections
- **Blood Diseases** (0 articles) — https://healthandpharma.net/posts?category=blood-diseases
- **Cancer** (4 articles) — https://healthandpharma.net/posts?category=cancer
- **Brain Diseases** (0 articles) — https://healthandpharma.net/posts?category=brain
- **Heart Diseases** (0 articles) — https://healthandpharma.net/posts?category=heart-diseases
- **Internal Diseases** (0 articles) — https://healthandpharma.net/posts?category=internal-diseases
- **Psychiatry** (4 articles) — https://healthandpharma.net/posts?category=psychiatry
- **Important Tests** (0 articles) — https://healthandpharma.net/posts?category=important-tests
- **Neurology** (23 articles) — https://healthandpharma.net/posts?category=neurology
- **Rheumatology** (2 articles) — https://healthandpharma.net/posts?category=rheumatology
- **Biotech** (19 articles) — https://healthandpharma.net/posts?category=biotech
- **FDA & EMA** (172 articles) — https://healthandpharma.net/posts?category=fda-ema
- **Clinical Trials** (89 articles) — https://healthandpharma.net/posts?category=clinical-trials
- **Pharma** (80 articles) — https://healthandpharma.net/posts?category=pharma
- **AI** (24 articles) — https://healthandpharma.net/posts?category=ai
- **New Discovery** (8 articles) — https://healthandpharma.net/posts?category=new-discovery
- **Pediatrics** (1 articles) — https://healthandpharma.net/posts?category=pediatrics
- **Digital Health** (42 articles) — https://healthandpharma.net/posts?category=digital-health
- **Cardiology** (1 articles) — https://healthandpharma.net/posts?category=cardiology
- **Genetic** (7 articles) — https://healthandpharma.net/posts?category=genetic
- **Gynecology** (0 articles) — https://healthandpharma.net/posts?category=gynecology
- **Health Tech** (0 articles) — https://healthandpharma.net/posts?category=health-tech
- **Medical Devices** (10 articles) — https://healthandpharma.net/posts?category=medical-devices
- **ONCOLife** (334 articles) — https://healthandpharma.net/posts?category=oncolife
- **Surgery** (1 articles) — https://healthandpharma.net/posts?category=surgery
- **Opinion** (11 articles) — https://healthandpharma.net/posts?category=opinion
- **Webinar** (25 articles) — https://healthandpharma.net/posts?category=webinar

## Authors

- **Hüseyin Kandemir** (148 articles) — https://healthandpharma.net/author/huseyin-kandemir
  As a medical journalist with over 20 years of experience, I have served as an Editor and Reporter for various magazines, newspapers, and online broadcasting platforms, consistently demonstrating a str...
- **Health and Pharma** (496 articles) — https://healthandpharma.net/author/health-and-pharma
  Health and Pharma is a new-generation international news and communication platform. We strive to be a top-tier trusted news outlet, delivering firsthand reports from reliable channels. Our goal is to...
- **Mithat Can Turan** (22 articles) — https://healthandpharma.net/author/mithat-can-turan
  I am a software developer and a 4th-year Computer Engineering student at the Turkish-German University. I have worked on numerous software projects, especially those related to healthcare. My primary...
- **Martin Sandhu** (2 articles) — https://healthandpharma.net/author/martin-sandhu
  Martin Sandhu is the CEO and founder of Nuom, a digital health transformation consultancy delivering service design to organisations in the healthcare industry. He aims to increase patient engagement...
- **Jamie Kalafchi** (1 articles) — https://healthandpharma.net/author/jamie-kalafchi
  Highly experienced Clinical Pharmacist with a strong background in pharmaceutical expertise and a knack for effective cross-functional communication to enhance patient care, products, and services. My...
- **Tracy Mokwe** (54 articles) — https://healthandpharma.net/author/tracy-mokwe
  With over 3 years of experience as a medical laboratory scientist and writer, I am passionate about translating complex scientific information into clear and accessible content. My expertise lies in m...
- **Iffi Wahla** (1 articles) — https://healthandpharma.net/author/iffi-wahla
  Iffi Wahla, Co-Founder and CEO of Edge, empowers healthcare businesses to bridge the skills gap through innovative AI solutions. With a focus on global hiring dynamics, Iffi advocates for smarter, tec...
- **Clifford Huntley
** (1 articles) — https://healthandpharma.net/author/clifford-huntley
  Clifford Huntley is head of research and development at Solspan, part of Kensington Systems, a leading provider of commercial solar carports. He is an expert when it comes to solar PV and carport desi...
- **Darron Antill** (1 articles) — https://healthandpharma.net/author/darron-antill
  
Darron has extensive experience in leading successful high-growth companies that specialise in security and analytics software and services and with specific focus on medical device manufacturers an...
- **Doron Sitbon** (1 articles) — https://healthandpharma.net/author/doron-sitbon
  Doron Sitbon is the Founder and CEO of Dot Compliance, a provider of AI-powered electronic quality management solutions for the life sciences industry.

- **Carine Cohen, PhD** (1 articles) — https://healthandpharma.net/author/carine-cohen
  Carine has 20+ years of experience in big pharma’s. Here, she speaks as a patient, with early Breast Cancer. After an initial response, her prognosis got compromised by disease progression in her lymp...

## Recent Articles (last 50)

- [FDA Approves Enhertu for Two New HER2-Positive Early Breast Cancer Indications](https://healthandpharma.net/fda-enhertu-trastuzumab-deruxtecan-breast-cancer-her2) — FDA & EMA | Health and Pharma | 2026-05-16
  The FDA approved Enhertu (trastuzumab deruxtecan) for two HER2-positive early breast cancer indications: neoadjuvant T-DXd followed by THP in Stage II or III disease and adjuvant T-DXd for residual invasive disease after neoadjuvant therapy.
- [FDA Approves Sonrotoclax as First BCL2 Inhibitor for R/R Mantle Cell Lymphoma](https://healthandpharma.net/fda-sonrotoclax-beqalzi-mantle-cell-lymphoma) — FDA & EMA | Health and Pharma | 2026-05-14
  FDA has granted accelerated approval to sonrotoclax (BEQALZI) for adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies, including a BTK inhibitor. In BGB-11417-201, sonrotoclax achieved a 52% overall response rate, 16% complete response rate,
- [Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer](https://healthandpharma.net/imfinzi-durvalumab-imjudo-bladder-cancer-volga) — Clinical Trials | Health and Pharma | 2026-05-14
  In the Phase III VOLGA trial, perioperative Imfinzi plus neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival versus radical cystectomy-based standard care in cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer.
- [FDA Approves First All-Oral INQOVI Plus Venetoclax Regimen for Newly Diagnosed AML](https://healthandpharma.net/fda-inqovi-decitabine-cedazuridine-venetoclax-aml) — FDA & EMA | Health and Pharma | 2026-05-14
  The FDA has approved INQOVI (decitabine and cedazuridine) plus venetoclax for newly diagnosed AML in adults aged 75 years or older, or those ineligible for intensive induction chemotherapy. In the Phase 2 ASCERTAIN-V study, 41.6% of patients achieved complete remission,
- [FDA Grants RMAT Designation to RZ-001, a Novel RNA Therapy for Hepatocellular Carcinoma](https://healthandpharma.net/fda-rmat-rz001-rna-therapy-hepatocellular-carcinoma-rznomics) — FDA & EMA | Health and Pharma | 2026-05-09
  The FDA has granted RMAT designation to RZ-001, Rznomics’ investigational trans-splicing ribozyme-based RNA therapy for hepatocellular carcinoma. The designation is supported by promising Phase 1b/2a safety and preliminary response data presented at AACR 2026.
- [FDA Approves Bizengri as First Targeted Therapy for NRG1 Fusion+ Cholangiocarcinoma](https://healthandpharma.net/fda-approves-bizengri-zenocutuzumab-cholangiocarcinoma) — FDA & EMA | Health and Pharma | 2026-05-09
  The FDA has approved zenocutuzumab-zbco (BIZENGRI) for adults with advanced, unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma after prior systemic therapy. In the Phase 2 eNRGy trial, the confirmed ORR was 36.8%
- [FDA Grants Fast Track Designation to RPTR-1-201 for Advanced Triple- Breast Cancer](https://healthandpharma.net/fda-fast-track-designation-rptr1-201-triple-breast-cancer) — FDA & EMA | Health and Pharma | 2026-05-08
  The FDA has granted Fast Track Designation to RPTR-1-201 for unresectable or metastatic triple-negative breast cancer after standard therapy failure or intolerance. The investigational TCR bispecific, now in Phase 1/2 testing, uses an engineered TCR and anti-CD3 domain
- [PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer](https://healthandpharma.net/esmo-breast26-phergain-chemotherapy-free-survival-breast-cancer) — ONCOLife | Hüseyin Kandemir | 2026-05-07
  New PHERGain data presented at #ESMObreast26 strengthen the rationale for chemotherapy de-escalation in selected patients with early HER2+ breast cancer. And about one-third of patients avoided chemotherapy, with nearly 90% remaining relapse-free five years after surgery.
- [FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma](https://healthandpharma.net/fda-designation-dubodencel-doc1021-cutaneous-melanoma) — FDA & EMA | Health and Pharma | 2026-05-07
  The FDA has granted Fast Track designation to dubodencel (DOC1021) for unresectable or metastatic cutaneous melanoma. The first-in-class, patient-derived, double-loaded dendritic cell therapy uses tumor lysate and amplified tumor-derived mRNA to stimulate broad anti-tumor immunity.
- [Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer](https://healthandpharma.net/rnase-h2-exposes-triple-breast-cancer) — ONCOLife | Hüseyin Kandemir | 2026-05-06
  Researchers at MD Anderson have identified RNase H2 as a key survival mechanism in triple-negative breast cancer, helping tumor cells tolerate high levels of DNA replication stress.
- [FDA Accepts IBTROZI sNDA After Durable Long-Term Benefit in Advanced ROS1+ Lung Cancer](https://healthandpharma.net/fda-taletrectinib-ibtrozi-snda-ros1-lung-cancer) — FDA & EMA | Health and Pharma | 2026-05-06
  The FDA has accepted the sNDA for IBTROZI® (taletrectinib), which aims to update the drug’s label with longer-term data in advanced ROS1-positive non-small cell lung cancer. In TRUST-I, TKI-naïve patients achieved a median duration of response of 49.7 months
- [ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit](https://healthandpharma.net/cancer-alk-mutation-immunotherapy-checkpoint-inhibitors) — ONCOLife | Hüseyin Kandemir | 2026-05-04
  A pan-cancer analysis of 2,930 patients across 11 tumor types found that ALK mutation was associated with significantly improved survival among patients treated with immune checkpoint inhibitors. Patients with ALK-mutant tumors had a 31% lower risk of death,
- [FDA ODAC Backs Truqap Combination for PTEN-Deficient Metastatic Prostate Cancer](https://healthandpharma.net/fda-truqap-prostate-cancer-capivasertib) — FDA & EMA | Health and Pharma | 2026-05-03
  FDA’s advisory committee has endorsed Truqap plus abiraterone and ADT as a treatment option with a favorable benefit-risk profile for patients with PTEN-deficient metastatic HS prostate cancer. In CAPItello-281, the combination reduced radiographic progression or death by 19%
- [Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk](https://healthandpharma.net/social-media-misinformation-skin-cancer-risk-sunscreen) — Clinical Trials | Health and Pharma | 2026-05-03
  A new American Academy of Dermatology survey finds that social media misinformation has driven more than 16 million U.S. adults toward higher skin cancer risk by leading them to reduce or stop using sunscreen.
- [Zeta Navigation System Gains FDA Clearance for Brain Tumor Biopsy and Neurosurgery](https://healthandpharma.net/fda-ai-zeta-navigation-system-brain-tumor-biopsy-surgery) — FDA & EMA | Health and Pharma | 2026-05-02
  The Zeta Navigation System has received FDA 510(k) clearance alongside the Zeta Stylet and Zeta Bolt, expanding real-time, AI-assisted image guidance for neurosurgery. The platform may improve access to millimeter-level navigation for brain tumor biopsies
- [FDA Approves Vepdegestrant, First PROTAC Therapy for ESR1+ ER+/HER2- Breast Cancer](https://healthandpharma.net/fda-vepdegestrant-veppanu-breast-cancer) — FDA & EMA | Health and Pharma | 2026-05-02
  FDA has approved vepdegestrant (VEPPANU), the first PROTAC therapy, for adults with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer after endocrine therapy progression. In VERITAC-2, vepdegestrant reduced risk of progression or death by 43%
- [SUNRISE-II Trial Begins Evaluating Ultrasound-Guided HIFU Ablation for Pancreatic Cancer](https://healthandpharma.net/suizenji-hifu-ablation-pancreatic-cancer) — Clinical Trials | Health and Pharma | 2026-05-01
  Sonire’s first U.S. study of ultrasound-guided, anesthesia-free HIFU ablation therapy has been launched for patients with unresectable pancreatic cancer. The Stanford-led, open-label trial will enroll patients to assess safety, and tolerability before first-line chemotherapy.
- [Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy](https://healthandpharma.net/restoring-proteostasis-boost-tcell-cancer-immunotherapy) — ONCOLife | Hüseyin Kandemir | 2026-04-30
  A new Cell study suggests that T cell exhaustion in tumors is driven in part by failed proteostasis, causing damaged and misfolded proteins to accumulate inside tumor-infiltrating lymphocytes. Restoring proteostasis may improved T cell function
- [OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer](https://healthandpharma.net/tlx597tx-radioligand-therapy-prostate-cancer-telix) — Clinical Trials | Health and Pharma | 2026-04-30
  Phase 2 OPTIMAL-PSMA dosimetry data suggest that TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, demonstrated low salivary gland and kidney uptake in metastatic castration-resistant prostate cancer.
- [AidaBREAST Gains FDA Breakthrough Status for Personalized Radiotherapy in Breast Cancer](https://healthandpharma.net/aidabreast-test-fda-radiotherapy-breast-cancer) — FDA & EMA | Health and Pharma | 2026-04-29
  AidaBREAST® received FDA Breakthrough Device designation as a multi-omic assay for women with stage I–IIa invasive breast cancer. The test estimates 10-year locoregional recurrence risk and predicts benefit from radiation therapy after breast surgery
- [Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma](https://healthandpharma.net/elranatamab-elrexfio-multiple-myelom-pfizer) — Clinical Trials | Health and Pharma | 2026-04-29
  The Phase 3 MagnetisMM-5 trial showed that elranatamab (ELREXFIO) significantly improved progression-free survival versus daratumumab plus pomalidomide and dexamethasone in adults with relapsed or refractory multiple myeloma.
- [Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer](https://healthandpharma.net/community-oncology-care-survival-breast-lung-cancer) — ONCOLife | Hüseyin Kandemir | 2026-04-28
  A real-world Flatiron Health analysis commissioned by the Community Oncology Alliance found that patients with de novo metastatic breast cancer and lung cancer treated in independent community oncology practices had survival outcomes exceeding SEER benchmarks.
- [Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer](https://healthandpharma.net/pembrolizumab-lenvatinib-clear-cell-gynaecological-cancer) — Clinical Trials | Health and Pharma | 2026-04-26
  The Phase 2 LARA trial reported encouraging activity for pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma, achieving a 40% objective response rate within 24 weeks and a median progression-free survival of 6.4 months.
- [Early CAR T-Cell Intervention Shows Disease-Eradication Potential in High-Risk Myeloma](https://healthandpharma.net/cart-cell-ciltacabtagene-smoldering-multiple-myeloma) — ONCOLife | Hüseyin Kandemir | 2026-04-24
  A Dana-Farber phase 2 trial suggests BCMA-directed CAR T-cell therapy may deliver deep early disease control in high-risk smoldering multiple myeloma. All 20 patients receiving cilta-cel achieved MRD negativity within two months and remained MRD-negative after 15.3 months
- [World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer](https://healthandpharma.net/nectin4-adc-breast-cancer-9mw2821-tnbc-mabwell) — Clinical Trials | Health and Pharma | 2026-04-24
  The world’s first Nectin-4-targeting ADC to enter Phase III development in triple-negative breast cancer is now being evaluated in locally advanced or metastatic disease. The randomized trial will compare 9MW2821 with investigator’s choice of chemotherapy in patients
- [Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC](https://healthandpharma.net/ibtrozi-taletrectinib-nsclc-lung-cancer) — ONCOLife | Health and Pharma | 2026-04-23
  Long-term pooled results from TRUST-I /-II trials show taletrectinib delivers durable benefit in advanced ROS1+ NSCLC, with an 89.8% response rate, 49.7-month median duration of response, and 46.1-month median progression-free survival in TKI-naïve patients.
- [FDA-Cleared Utepreva Device Aims to Improve Early Endometrial Cancer Detection](https://healthandpharma.net/fda-utepreva-device-endometrial-cancer-detection-test) — Cancer | Health and Pharma | 2026-04-22
  The FDA 510(k)-cleared Utepreva Endometrial Sampler, a single-use device designed to support early diagnostic evaluation of endometrial cancer, may help improve diagnostic assessment.
- [Opaganib Shows Dual Preclinical Promise in Neuroblastoma and Triple- Breast Cancer](https://healthandpharma.net/opaganib-neuroblastoma-breast-cancer) — ONCOLife | Health and Pharma | 2026-04-22
  New preclinical data presented at AACR 2026 suggest opaganib may improve outcomes in two hard-to-treat cancers. In high-risk neuroblastoma models, it enhanced oxaliplatin plus doxorubicin activity by destabilizing n-Myc and promoting apoptosis.
- [Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer](https://healthandpharma.net/ozekibart-folfiri-metastatic-colorectal-cancer) — ONCOLife | Health and Pharma | 2026-04-22
  Updated Phase 1/2 data show that ozekibart plus FOLFIRI produced a 20% objective response rate and an 87% disease control rate in heavily pretreated metastatic or unresectable colorectal cancer, where historical response rates are typically 1% to 6%.
- [FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma](https://healthandpharma.net/fda-breakthrough-viral-mrd-liquid-biopsy-hepatocellular-carcinoma) — FDA & EMA | Health and Pharma | 2026-04-21
  The FDA has granted Breakthrough Device Designation to CatCHimera, the first MRD liquid biopsy in hepatocellular carcinoma to track HBV-host integration junctions rather than somatic mutations. In clinical studies, it detected viral-host DNA in 98% of pre-surgical plasma samples,
- [PLN-101095 Plus Pembrolizumab Shows Durable Responses in ICI-R Solid Tumors](https://healthandpharma.net/pln-101095-checkpoint-inhibitor-pembrolizumab-solid-tumors) — ONCOLife | Health and Pharma | 2026-04-20
  Updated Phase 1 data presented at AACR 2026 suggest PLN-101095 plus pembrolizumab may help overcome secondary ICI resistance in advanced solid tumors. Among confirmed responders, average maximum tumor reduction reached 89% and median treatment duration was 19 months.
- [FDA Gives Priority Review to PADCEV Plus Pembrolizumab in MI Bladder Cancer](https://healthandpharma.net/fda-priority-padcev-pembrolizumab-mi-bladder-cancer) — FDA & EMA | Health and Pharma | 2026-04-20
  The FDA has granted Priority Review to a supplemental application for PADCEV plus pembrolizumab in muscle-invasive bladder cancer, regardless of cisplatin eligibility. In the Phase 3 EV-304 trial, the regimen reduced the risk of recurrence, progression, or death by 47%
- [AACR26 Data Show Multi-Biomarker MCED Approach Improves Early Cancer Detection](https://healthandpharma.net/aacr2026-abbott-biomarker-mced-cancer-detection) — ONCOLife | Health and Pharma | 2026-04-17
  At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and protein signals to improve cancer detection. In 3,163 samples, 47.1% of positive calls were methylation-only, 7.4% protein-only, and 45.5% dual-signal.
- [FDA Grants Breakthrough Status to First Urine-Based Multi-Cancer Early Detection Test](https://healthandpharma.net/fda-breakthrough-urine-cancer-detection-test-toby) — ONCOLife | Health and Pharma | 2026-04-16
  TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform granted this status. The test analyzes urinary VOCs using spectroscopy and machine learning from a single sample.
- [Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer](https://healthandpharma.net/daraxonrasib-metastatic-pancreatic-cancer) — ONCOLife | Health and Pharma | 2026-04-15
  Daraxonrasib significantly improved outcomes in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, meeting all primary and key secondary endpoints. In the intent-to-treat population, median overall survival was 13.2 months versus 6.7 months with chemotherapy.
- [AI Nodule Detection Helps Sarasota Memorial Reach 75% Early Lung Cancer Diagnosis](https://healthandpharma.net/ai-nodule-detection-sarasota-memorial-lung-cancer) — AI | Health and Pharma | 2026-04-15
  Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II. The program used AI to review more than 430,000 radiology reports annually and flag incidental pulmonary nodules.
- [Illumina Launch 100 K Genome Effort to Advance Cancer and Rare Disease Research](https://healthandpharma.net/illumina-d3b-genome-pediatric-cancer-rare-disease) — AI | Health and Pharma | 2026-04-15
  Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, two areas where fragmented data and delayed diagnosis continue to limit progress.
- [Zenocutuzumab Gains NCCN Support as FDA Review Advances in Cholangiocarcinoma](https://healthandpharma.net/bizengri-zenocutuzumab-fda-bla-cholangiocarcinoma) — FDA & EMA | Health and Pharma | 2026-04-15
  Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, zenocutuzumab-zbco, seeking approval in adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.
- [Phase 2 Data Position Trastuzumab Pamirtecan as a Promising Option in Endometrial Cancer](https://healthandpharma.net/biontech-trastuzumab-pamirtecan-her2-endometrial-cancer) — ONCOLife | Health and Pharma | 2026-04-13
  BioNTech and DualityBio reported encouraging Phase 2 results for trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, in pretreated, HER2-expressing recurrent endometrial cancer.
- [FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer](https://healthandpharma.net/fda-ifinatamab-deruxtecan-essc-lung-cancer) — FDA & EMA | Health and Pharma | 2026-04-13
  FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with extensive-stage small cell lung cancer, ES-SCLC, whose disease progressed on or after platinum-based chemotherapy.
- [Mocertatug Rezetecan Shows Strong Responses in Ovarian and Endometrial Cancers](https://healthandpharma.net/gsk-mocertatug-rezetecan-ovarian-endometrial-cancers) — FDA & EMA | Health and Pharma | 2026-04-12
  GSK has reported encouraging early clinical data from the global phase I BEHOLD-1 trial of mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, in patients with platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer,
- [MD Anderson Study Identifies DPY30 as Therapeutic Target in Pancreatic Cancer](https://healthandpharma.net/md-anderson-dyp30-biomarker-target-pancreatic-cancer) — ONCOLife | Health and Pharma | 2026-04-11
  Researchers at MD Anderson identified DPY30 as a key biomarker and epigenetic regulator that enables pancreatic tumors to tolerate replication stress and escape immune attack. Loss of DPY30 destabilized replication forks, increased T-cell infiltration
- [Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer](https://healthandpharma.net/dhodh-radiotherapy-lung-cancer-ferroptosis-leflunomide) — ONCOLife | Health and Pharma | 2026-04-10
  Researchers from MD Anderson identified DHODH as a key metabolic driver of radiotherapy resistance in lung cancer. Radiation increased DHODH activity, enabling tumor cells to suppress ferroptosis and support DNA repair.
- [New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy](https://healthandpharma.net/blocks-nmd-hidden-tumor-immunotherapy-cancer) — ONCOLife | Hüseyin Kandemir | 2026-04-10
  A new study led by UCL researchers suggests that making cancer cells more visible to the immune system could broaden the impact of immunotherapy across multiple tumor types. Published in Immunity and based on data from more than 1,000 patients
- [Neladalkib Reaches FDA Review for TKI-Pretreated ALK+ Non-Small Cell Lung Cancer](https://healthandpharma.net/neladalkib-fda-alk-nsclc-lung-cancer) — FDA & EMA | Health and Pharma | 2026-04-09
  Neladalkib has been submitted for FDA review in TKI pre-treated advanced ALK-positive NSCLC, based on data from the global ALKOVE-1 Phase 1/2 trial. The brain-penetrant, ALK-selective inhibitor showed encouraging overall and intracranial activity
- [New Radio-Theranostic Promises to Broaden Targeted Radiation in Solid Tumors](https://healthandpharma.net/betabart-radiotheranostic-radiation-olid-tumors) — ONCOLife | Hüseyin Kandemir | 2026-04-04
  Researchers developed MIL33B, a high-affinity antibody that selectively targets the tumor-associated 4Ig-B7-H3 isoform while sparing the soluble decoy form. Radioligand therapy with 90Y-MIL33B achieved 53% long-term survival and triggered CD8+ T-cell activation with immune memory.
- [FDA Grants Breakthrough Status to WU-CART-007 for T-Cell Leukemias and Lymphomas](https://healthandpharma.net/fda-breakthrough-wu-cart-tcell-leukemias-lymphomas) — FDA & EMA | Health and Pharma | 2026-04-01
  FDA has granted Breakthrough Therapy designation to WU-CART-007, an off-the-shelf CAR-T therapy for relapsed or refractory T-ALL and T-LL, two aggressive T-cell cancers with poor outcomes. In a phase 1 study, the therapy achieved a 91% overall response rate and 72.7% complete remission rate
- [Immunotherapy Boosts Chemo Cutting Recurrence Risk by 50% in Colon Cancer](https://healthandpharma.net/immunotherapy-atezolizumab-boosts-chemotherapy-dmmr-colon-cancer) — ONCOLife | Hüseyin Kandemir | 2026-03-30
  Adding to adjuvant mFOLFOX6 significantly improved outcomes in resected stage III dMMR colon cancer, reducing recurrence or death risk by 50% versus chemotherapy alone. In the phase 3 ATOMIC trial, 3-year disease-free survival reached 86.3% with the combination
- [New IHC Biomarker Test Predicts Which Gastric Cancer Patients Benefit from Immunotherapy](https://healthandpharma.net/ihc-biomarker-test-predict-gastric-cancer-immunotherapy) — ONCOLife | Hüseyin Kandemir | 2026-03-30
  Researchers from Peking University discovered a tumor-specific biomarker that can predict which gastric cancer patients will benefit from immunotherapy before surgery. In the study, tsMHC-II-positive tumors showed higher pathological complete response rates, 36.84% versus 11.11%
- [Nonviral Gene Delivery Platform Offers Promise for Cancer Treatment and Cell Therapy](https://healthandpharma.net/nanoparticle-nonviral-gene-therapy-promise-cancer) — ONCOLife | Hüseyin Kandemir | 2026-03-30
  University of Michigan researchers developed serum albumin-based nanoparticles that delivered plasmid DNA and mRNA into multiple human cell types without viral vectors. The approach could support safer gene therapies for cancer and many other genetic diseases

## Citation Format

Author Name. "Article Title." Health and Pharma, Date. URL.

## Medical Disclaimer

Content is for informational purposes only. Not a substitute for professional medical advice.